Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P62753
UPID:
RS6_HUMAN
Alternative names:
40S ribosomal protein S6; Phosphoprotein NP33
Alternative UPACC:
P62753; P08227; P10660; Q4VBY7; Q8N6Z7
Background:
Small ribosomal subunit protein eS6, also known as 40S ribosomal protein S6 and Phosphoprotein NP33, is a crucial component of the 40S small ribosomal subunit. It plays a pivotal role in controlling cell growth and proliferation by selectively translating specific classes of mRNA. As part of the SSU processome, it contributes to the assembly of the small eukaryotic ribosomal subunit in the nucleolus, facilitating RNA folding, modifications, rearrangements, and targeted degradation of pre-ribosomal RNA.
Therapeutic significance:
Understanding the role of Small ribosomal subunit protein eS6 could open doors to potential therapeutic strategies.